## Section 9 510(K) SUMMARY

**SPONSOR:** 

Boston Scientific Corporation (BSC)

Microvasive Endoscopy Division

One Boston Scientific Place

Natick, MA 01760

CONTACT/SUBMITTER:

Lisa Quaglia

Regulatory Affairs Manager

Tel: 508-650-8267

DATE OF SUBMISSION:

September 19, 2001

**DEVICE:** 

Autotome™ RX

Trade Name: Common Name: Autotome™ RX Sphincterotome

Classification:

**Endoscope and Accessories** 

Classified Under 21 CFR Part 876, §4300.

Classified as a Class II Device.

PREDICATE DEVICE:

Rapid Exchange™ Cannulating Sphincterotome

(K970053, Ultratome RX)

**DEVICE DESCRIPTION:** 

The proposed Autotome™ RX is a triple lumen

sphincterotome with controlled orientation and rotation features. It is compatible with the Boston Scientific Microvasive® Endoscopy's Rapid Exchange™ platform, and is capable of accommodating a .035" guidewire while allowing simultaneous injection through an

adjacent lumen.

**INTENDED USE:** 

The Autotome™ RX is indicated for use in

transendoscopic sphincterotomy of the Papilla of Vater and/or the Sphincter of Oddi. This device can also be

used to cannulate and inject contrast medium.

COMPARISON OF CHARACTERISTICS:

The proposed device is substantially equivalent to currently marketed devices used for transendoscopic sphincterotomy of the Papilla of Vater and/or the Sphincter of Oddi, and for injection of contrast media

into the biliary and pancreatic ductal systems.

**PERFORMANCE DATA:** 

The proposed device is substantially equivalent to currently marketed Rapid Exchange<sup>TM</sup> Cannulating Sphincterotome in terms of performance characteristics

tested and biocompatibility.



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

## OCT 1 9 2001

Ms. Lisa M. Quaglia Regulatory Affairs Manager Microvasive Endoscopy Boston Scientific Corporation One Boston Scientific Place NATICK MA 01760-1537 Re: K013153

Trade/Device Name: Ultratome™ RX

Model # 4515, 4516

Regulation Number: 21 CFR 876.4300

Regulation Name: Endoscopic electrosurgical

unit and accessories

Regulatory Class: II Product Code: 78 KNS Dated: September 19, 2001 Received: September 20, 2001

## Dear Ms. Quaglia:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of this letter:

| 8xx.1xxx                         | (301) 594-4591 |
|----------------------------------|----------------|
| 876.2xxx, 3xxx, 4xxx, 5xxx       | (301) 594-4616 |
| 884.2xxx, 3xxx, 4xxx, 5xxx, 6xxx | (301) 594-4616 |
| 892.2xxx, 3xxx, 4xxx, 5xxx       | (301) 594-4654 |
| Other                            | (301) 594-4692 |

Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <a href="http://www.fda.gov/cdrh/dsma/dsmamain.html">http://www.fda.gov/cdrh/dsma/dsmamain.html</a>.

Sincerely yours,

Vancy Chroadon
Nancy C. Brogdon

Director, Division of Reproductive, Abdominal, and Radiological Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

## **Indications for Use Statement**

K013153

510(k) Number (if known)

| Device Name                         | Autotome™ RX   |
|-------------------------------------|--|
| Indications for Use                 | The Autotome™ RX is indicated for use in transendoscopic sphincterotomy of the Papilla of Vater and/or the Sphincter of Oddi. The device can also be used to cannulate and inject contrast medium. |
|                                     |  |
|                                     |  |
|                                     |  |
|                                     |  |
| PLEASE DO NOT V                     | VRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED   |
|                                     | RH, Office of Device Evaluation (ODE)  |
|                                     | RH, Office of Device Evaluation (ODE)  OR Over the Counter Use   |
| Concurrence of CDI Prescription Use | RH, Office of Device Evaluation (ODE)  OR Over the Counter Use   |

Page 1 of 1